Snehal Patel - Greenwich Lifesciences CFO CEO
| GLSI Stock | USD 14.25 0.32 2.20% |
Insider
Snehal Patel is CFO CEO of Greenwich Lifesciences
| Age | 60 |
| Address | Building 14, Stafford, TX, United States, 77477 |
| Phone | 832 819 3232 |
| Web | https://greenwichlifesciences.com |
Latest Insider Transactions
| 2024-09-26 | Acquired 1500 shares @ 14.63 | View | |
| 2024-08-05 | Acquired 5500 shares @ 13.18 | View | |
| 2024-07-23 | Acquired 1500 shares @ 15.89 | View | |
| 2024-06-13 | Acquired 174825 shares @ 14.3 | View | |
| 2024-04-01 | Acquired 3000 shares @ 19.08 | View | |
| 2024-03-22 | Acquired 2500 shares @ 19.98 | View | |
| 2024-03-20 | Acquired 1500 shares @ 17.68 | View | |
| 2024-03-04 | Acquired 4100 shares @ 13.03 | View | |
| 2024-02-15 | Acquired 12700 shares @ 11.07 | View |
Snehal Patel Latest Insider Activity
Tracking and analyzing the buying and selling activities of Snehal Patel against Greenwich Lifesciences stock is an integral part of due diligence when investing in Greenwich Lifesciences. Snehal Patel insider activity provides valuable insight into whether Greenwich Lifesciences is net buyers or sellers over its current business cycle. Note, Greenwich Lifesciences insiders must abide by specific rules, including filing SEC forms every time they buy or sell Greenwich Lifesciences'shares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Snehal Patel over two weeks ago Acquisition by Snehal Patel of 2000 shares of Greenwich Lifesciences at 9.72 subject to Rule 16b-3 | ||
Snehal Patel over a month ago Acquisition by Snehal Patel of 12000 shares of Greenwich Lifesciences at 7.91 subject to Rule 16b-3 | ||
Snehal Patel over two months ago Acquisition by Snehal Patel of 1500 shares of Greenwich Lifesciences at 14.63 subject to Rule 16b-3 | ||
Snehal Patel over three months ago Acquisition by Snehal Patel of 2000 shares of Greenwich Lifesciences at 13.81 subject to Rule 16b-3 |
Greenwich Lifesciences Management Efficiency
The company has return on total asset (ROA) of (0.7245) % which means that it has lost $0.7245 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.2367) %, meaning that it created substantial loss on money invested by shareholders. Greenwich Lifesciences' management efficiency ratios could be used to measure how well Greenwich Lifesciences manages its routine affairs as well as how well it operates its assets and liabilities. The current Return On Tangible Assets is estimated to decrease to -1.34. The Greenwich Lifesciences' current Return On Capital Employed is estimated to increase to -1.32. As of now, Greenwich Lifesciences' Net Tangible Assets are increasing as compared to previous years. Other Assets is expected to grow at the current pace this year, while Total Assets are projected to decrease to under 6.6 M.Similar Executives
| Showing other executives | INSIDER Age | ||
| BS CPA | Inhibrx | 42 | |
| Susan MS | Eliem Therapeutics | N/A | |
| James JD | Eliem Therapeutics | 58 | |
| Patrick Amstutz | Molecular Partners AG | 49 | |
| Quinn Deveraux | Inhibrx | N/A | |
| Mark Lappe | Inhibrx | 57 | |
| Kenneth MD | Cue Biopharma | 64 | |
| Seth Lewis | Molecular Partners AG | N/A | |
| Andreas EMBA | Molecular Partners AG | 58 | |
| Erin Lavelle | Eliem Therapeutics | 47 | |
| Steven Almo | Cue Biopharma | 63 | |
| Alexander Zurcher | Molecular Partners AG | 49 | |
| Michael Pitzner | Molecular Partners AG | N/A | |
| MBA MD | Eliem Therapeutics | 63 | |
| Robert MBA | Eliem Therapeutics | 56 | |
| , MBA | Molecular Partners AG | 51 | |
| Thomas Schwerzmann | Molecular Partners AG | N/A | |
| JD MSc | Cue Biopharma | 61 | |
| Dr III | Cue Biopharma | 48 | |
| Jo PalmerPhillips | Eliem Therapeutics | N/A | |
Management Performance
| Return On Equity | -1.24 | ||||
| Return On Asset | -0.72 |
Greenwich Lifesciences Leadership Team
Elected by the shareholders, the Greenwich Lifesciences' board of directors comprises two types of representatives: Greenwich Lifesciences inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Greenwich. The board's role is to monitor Greenwich Lifesciences' management team and ensure that shareholders' interests are well served. Greenwich Lifesciences' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Greenwich Lifesciences' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Snehal Patel, CFO CEO | ||
| Eric Rothe, Founder Director | ||
| Frank MD, Chief Director | ||
| Jaye Thompson, Vice Affairs | ||
| Christine Fischette, VP Development |
Greenwich Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Greenwich Lifesciences a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.24 | ||||
| Return On Asset | -0.72 | ||||
| Current Valuation | 185.7 M | ||||
| Shares Outstanding | 13.14 M | ||||
| Shares Owned By Insiders | 52.92 % | ||||
| Shares Owned By Institutions | 8.69 % | ||||
| Number Of Shares Shorted | 470.74 K | ||||
| Price To Book | 38.44 X | ||||
| EBITDA | (9.32 M) | ||||
| Net Income | (8.89 M) |
Currently Active Assets on Macroaxis
When determining whether Greenwich Lifesciences offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Greenwich Lifesciences' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Greenwich Lifesciences Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Greenwich Lifesciences Stock:Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Greenwich Lifesciences. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in state. For more detail on how to invest in Greenwich Stock please use our How to Invest in Greenwich Lifesciences guide.You can also try the Earnings Calls module to check upcoming earnings announcements updated hourly across public exchanges.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Greenwich Lifesciences. If investors know Greenwich will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Greenwich Lifesciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.81) | Return On Assets (0.72) | Return On Equity (1.24) |
The market value of Greenwich Lifesciences is measured differently than its book value, which is the value of Greenwich that is recorded on the company's balance sheet. Investors also form their own opinion of Greenwich Lifesciences' value that differs from its market value or its book value, called intrinsic value, which is Greenwich Lifesciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Greenwich Lifesciences' market value can be influenced by many factors that don't directly affect Greenwich Lifesciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Greenwich Lifesciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Greenwich Lifesciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Greenwich Lifesciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.